Compare Raytheon Technologies Corp (RTX) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raytheon Technologies Corp vs Tenet Healthcare Corporation — how do they compare? Raytheon Technologies Corp trades at $194.08 (market cap $261.85B), while Tenet Healthcare Corporation trades at $196.03 (market cap $16.74B). The key difference: Raytheon Technologies Corp is far larger — about 15.6× Tenet Healthcare Corporation's market cap, and Raytheon Technologies Corp pays a 1.5% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.
| RTX | THC | |
|---|---|---|
Market Cap | $261.85B | $16.74B |
Sector | Industrials | Health |
52-Week High | $212.16 | $244.80 |
52-Week Low | $149.17 | $148.38 |
Enterprise Value | $293.97B | $26.99B |
Dividend Yield | 1.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RTX trades at $193.51, down 0.44% today, with a bullish technical signal and strong analyst support. Recent contract wins, including a $515 million Navy radar deal (PRNewsWire, June 3, 2026), and earnings beats in Q4 2025 and Q1 2026 highlight operational momentum. Revenue growth accelerated to $88.6 billion in 2025, with net income margin improving to 8.03%. The stock faces resistance near $196-$199, with support at $192.
The outlook remains positive given defense spending tailwinds and production expansions, but elevated P/E of 36.48 poses valuation risk. Analysts project 10% upside to a $213 consensus target, with no sell ratings. Key risks include debt levels and geopolitical volatility affecting contracts.
Tenet Healthcare (THC) trades at $194.38, down 0.27% on the day, with a neutral technical signal despite strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $4.82 exceeding expectations of $4.17. Valuation metrics appear attractive with a P/E of 10.14 and P/S of 0.79, while profitability remains robust with 82.47% gross margins and 37.87% ROE. Recent news highlights the company's expanding outpatient footprint through USPI as a key growth driver.
THC presents a compelling investment case with strong analyst support (81% buy ratings) and a $235.88 price target representing 21% upside potential. The company's solid earnings momentum and defensive healthcare positioning during market volatility provide stability. Key risks include execution challenges in outpatient expansion and potential regulatory headwinds affecting hospital operations. Cash flow trends show improvement with projected net cash flow narrowing from -$136M in 2025 to -$32M in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
